OCGN$0.7352+1.44%
Ocugen, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$249.31M
Float & O/S:
Inst Own:
DilutionScan read 44 of Ocugen, Inc.'s SEC filings and found 3 warrant series, 3 convertibles, 2 shelf registrations and 4 completed offerings on file for OCGN. The latest dilution event on file is an offering on May 14, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
OCGN
Going-concern warning, negative equity
Snapshot
Ocugen is a clinical-stage biotech with almost no product revenue ($4.4M in FY 2025) and a net loss of $67.8M, several times its revenue. It burned $57.1M in free cash flow last year and now shows negative stockholders' equity of -$16.6M.
What's Happening Right Now
- : Ocugen's Q2 2026 10-Q discloses going-concern doubt, negative stockholders' equity of -$16.6M, and a widened quarterly net loss of $24.9M despite holding $100.1M in cash after a $130M convertible notes deal.
- : Ocugen dosed the first patient in its Phase 3 trial of OCU410 for geographic atrophy, a program that holds FDA RMAT designation and targets a possible 2028 BLA filing.
- : Ocugen scheduled a September 21, 2026 special meeting asking shareholders to raise authorized shares from 390 million to 640 million, driven by covenants on its new convertible notes.
- : Ocugen posted a Q2 loss of $0.07 per share, missing the $0.05 estimate, with per-share losses wider than a year earlier even as revenue beat forecasts.
- : Ocugen signed a binding term sheet to license OCU400 in the Middle East and North Africa for up to $4M in near-term payments, up to $255M in sales milestones, and a 22% royalty.
